| protein
| target of activating factor 2 (ATF2) in chondrocytes |
|
downstream target of BRAF  |
|
communication between ATM and cyclin D1 may be required for maintenance of genomic integrity achieved by rapid arrest of the cell-cycle, and that disruption of this crosstalk may increase susceptibility to cancer |
|
interacting with INSM1 (interaction could disrupt CDK4 binding during the normal cell cycle) |
|
CDC27 directs CCND1 to alternative degradation by APC/C |
|
CCND1–RUNX3 interaction interferes with the RUNX3–EP300 interaction, leading to the inhibition of transcriptional activation by RUNX3, downregulation of CDKN1A expression, and the blocking of the RUNX3-dependent inhibition of cancer cell proliferation |
|
interacting with SSB (role of SSB in cell proliferation and CCND1 expression demonstrating for the first time an overexpression of the RNA-binding protein SSB in solid tumors.) |
|
bound to a voltage-dependent anion channel through its central domain, and it competes with hexokinase 2 for binding to this channel |
|
directly binds RAD51, and CCND1-RAD51 interaction is induced by radiation |
|
inhibits NFKB transcriptional activity through a corepressor function that can be reverted by over-expressing RAC3 |
|
YY1 inhibited CDKN1A complex formation with CDK4 and CCND1 |
|
inhibited the activity of MLXIPL by regulating the glucose-sensing motif of this transcription factor |
|
direct relationship between USP18 and CCND1 (but not cyclin E) expression |
|
CARD10 contributes to malignant cell growth by facilitating cell cycle progression through NFKB mediated upregulation of CCND1 |
|
FAM60A promotes the retention of HDAC1 but not SIN3A at the CCND1 promoter in asynchronously growing cells |
|
PAX2 is a positive regulator of expression of CCND1 (PAX2 induces CCND1 through AP1) |
|
ROCK1 and ROCK2 could promote vascular smooth muscle cells (VSMC) proliferation through ERK nuclear translocation, regulating the expression of PCNA and cyclin D1 protein |
|
EYA1 phosphatase regulates cell-cycle control via transcriptional complex formation at the CCND1 promoter |
|
NUMBL could decrease the expression of TRAF6, CCND1, and MMP9 and increase the expression of CASP3 |
|
KDM5A upregulated expression of CCND1 and CCNE1 while suppressing the expression of cyclin-dependent kinase inhibitor p27 (CDKN1B), each contributing to KDM5A-mediated cell proliferation |
|
CCND1, a key mediator of cell growth during tissue regeneration, is a GLI1 transcriptional target, binding to the CCND1 promoter and regulating its activity and expression |
|
nuclear IGF2BP3-HNRNPM complex is important for the efficient synthesis of CCND1, CCND3 and CCNG1 and for the proliferation of human cancer cells |
|
novel function of CCND1 in promoting cell cycle progression by enhancing STK38/STK38L kinase activity independent of CDK4 |
|
CSF2 accelerated the G1/S phase transition in endothelial progenitor cells (EPCs) by upregulating the expression of CCND1 and CCNE1 |
|
up-regulation of CCND1 and BCL2A1 by insulin is involved in osteoclast proliferation |
|
MYF5 enhances early myogenesis in part by coordinately elevating CCND1 transcription and CCND1 mRNA translation |
|
ZNRF2 appeared to augment MTOR and its downstream targets CCND1 and CDK in non-small cell lung cancer cells |
|
CIAPIN1 played an important role in the proliferation of liver cancer cells through increasing the expressions of cell cycle related proteins CCND1, CDK2, CDK4, and CCNE |
|
SHCBP1 promoted cell cycle progression by regulating the CDK4& |
|
8209;CCND1 cascade and suppressed CASP3, caspase PARP& |
|
8209;dependent apoptotic pathways |
|
TCEAL7 regulates CCND1 expression through MYC-binding E-box sequences |
|
ZNF322 positively regulates transcription of alpha-adducin (ADD1) and cyclin D1 (CCND1) to promote tumorgenicity of lung cancer |
|
NFIC may contribute to postnatal chondrocyte proliferation by inhibiting CDKN1A expression and by increasing the stability of CCND1 protein |
|
USP27X binds to and stabilizes CCND1 in a catalytically dependent manner by negatively regulating its ubiquitination |
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
| fusion
|
|
|
| |
fused with TACSTD2 in cancer cells, fused with Igh in t(11;14) (q13;q32) | | tumoral
|
| amplification
|
|
| |
amplified in mantle cell lymphoma(same as BCL1, D11S287E), endometrial cancer | | tumoral
|
|
| --low
|
| |
in T-cell leukemia | | tumoral
|
| translocation
|
|
| |
t(6;11)(p21;q13), t(1;11)(p13;q13), t(7;11)(q11.2;q13), and t(5;11)(q35; q13) in renal oncocytoma | | tumoral
|
|
| --over
|
| |
in parathyroid adenoma, breast (stimulatory effect of estradiol and prolactin) carcinoma | | tumoral
|
| amplification
|
|
| |
coamplified with SHANK2, and CTT1 in oral squamous cell carcinoma | | tumoral
|
| deletion
|
|
| |
deletion in mantle cell lymphoma, associated with increased proliferation rate and shorter survival | | tumoral
|
| translocation
|
|
| |
in parathyroid adenomas | | tumoral
|
| amplification
|
|
| |
in breast cancer, alone or with PPFIA1 | | constitutional
|
|
| --over
|
| |
perturbs DNA replication and induces replication-associated DNA double-strand breaks in acquired radioresistant cells | |
